Emyria Limited (ASX:EMD)

Market Cap	29.84M +117.0%
Revenue (ttm)	2.29M +29.3%
Net Income	-4.55M
EPS	-0.01
Shares Out	806.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	730,062
Average Volume	2,658,192
Open	0.0390
Previous Close	0.0370
Day's Range	0.0380 - 0.0390
52-Week Range	0.0230 - 0.0780
Beta	0.05
RSI	27.09
Earnings Date	May 27, 2026

About Emyria

Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leedervi...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In fiscal year 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.